文献速递泌尿生殖与妇科肿瘤放疗

单机构前瞻性试验:19 Gy 单次高剂量率近距离放疗治疗低危和中危前列腺癌的五年结局

Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-02-13

该单机构前瞻性试验纳入 68 例低危或中危前列腺癌患者,接受 19 Gy 单次高剂量率近距离放疗,中位随访 3.9 年。5 年估计无病生存率为 77.2%,活检证实的局部失败率为 18.8%,慢性 2 级泌尿生殖毒性为 14.7%。作者认为毒性低,但生化和局部失败率高于预期,提示该剂量可能不足,需要进一步研究确定最佳单次剂量。

要点

  • 68 例低危或中危前列腺癌患者接受 19 Gy 单次高剂量率近距离放疗,中位随访 3.9 年。
  • 5 年估计无病生存率为 77.2%,活检证实的局部失败率为 18.8%。
  • 慢性 2 级泌尿生殖毒性为 14.7%,无 3 级泌尿毒性;1 例发生短暂 3 级腹泻。

核心结论

  • 延长随访后,19 Gy 单次高剂量率近距离放疗的毒性率仍然较低。
  • 但生化和局部失败率高于预期,引发对该剂量是否足够的担忧。
  • 需要进一步研究确定最佳的单次高剂量率近距离放疗剂量,目前单次治疗不应在临床试验之外提供。

研究设计与样本

  • 单机构前瞻性试验,纳入 68 例低危或中危前列腺癌患者。
  • 患者接受经直肠超声引导下前列腺间质植入,随后进行处方剂量为 19 Gy 的单次高剂量率近距离放疗。
  • 排除前列腺体积 >50 cm3、因泌尿症状服用 α 受体阻滞剂、或基线美国泌尿协会症状评分 >12 的患者。

主要发现

  • 中位随访 3.9 年,中位年龄 62 岁,治疗时中位腺体体积 35 cm3。
  • 92.6% 的患者为 T1 期疾病,63.2% 的 Gleason 评分为 6,治疗前中位前列腺特异性抗原为 5.0 ng/mL。
  • 慢性 2 级泌尿生殖毒性为 14.7%,无 3 级泌尿毒性;1 例患者发生 2 级及以上直肠毒性(3 级腹泻),为短暂性并经内科处理缓解。
  • 5 年估计无病生存率为 77.2%,低危与中危患者之间无显著差异。
  • 随访期间 1 例患者发生远处转移;5 年活检证实的局部失败率为 18.8%,发生于治疗后中位间隔 4.0 年;随访期间无死亡发生。

临床怎么用

  • 作者认为,目前单次分割治疗不应在临床试验之外提供。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To update outcome and toxicity results of a prospective trial of 19-Gy single-fraction high-dose-rate (HDR) brachytherapy for men with low- and intermediate-risk prostate cancer. METHODS AND MATERIALS: Patients were treated on a prospective study of single-fraction HDR brachytherapy. All patients had low- or intermediate-risk prostate cancer. Patients with prostate volumes >50 cm3, taking alpha-blockers for urinary symptoms, or with baseline American Urologic Association symptom scores >12 were ineligible. Patients underwent transrectal ultrasound-guided interstitial implant of the prostate followed by single-fraction HDR brachytherapy to a prescription dose of 19 Gy. RESULTS: Sixty-eight patients were enrolled with a median follow-up of 3.9 years. Median age was 62 years. Median gland volume at the time of treatment was 35 cm3, 92.6% of patients had T1 disease, 63.2% had a Gleason score of 6, and median pretreatment prostate-specific antigen was 5.0 ng/mL. Chronic grade 2 genitourinary toxicity was 14.7%. No grade 3 urinary toxicity occurred. A single patient experienced grade 2+ rectal toxicity (grade 3 diarrhea) that was transient and resolved with medical management. The 5-year estimated disease-free survival was 77.2% with no significant difference between low- and intermediate-risk patients. A single patient developed distant metastases during the follow-up period. Biopsy-proven local failure at 5 years was 18.8%, occurring at a median interval of 4.0 years posttreatment. No deaths occurred during follow-up. CONCLUSIONS: With extended follow-up, toxicity rates after single-fraction 19-Gy HDR brachytherapy remain low. Higher-than-expected rates of biochemical and local failure, however, raise concerns regarding the adequacy of this dose. Additional investigation to define the optimal single-fraction HDR brachytherapy dose is warranted, and single-fraction treatment currently should not be offered outside the context of a clinical trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Siddiqui ZA, Gustafson GS, Ye H, et al. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 30771408. doi:10.1016/j.ijrobp.2019.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。